Nikolaos Giannelos

Waver, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Accelerated Stability Studies: A Frequentist-Bayesian Hybrid Simulation Approach Implemented in the AccelStab R Package.

Accelerated Stability Studies: A Frequentist-Bayesian Hybrid Simulation Approach Implemented in the AccelStab R Package.

Journal: Pharmaceutical statistics
Published: October 15, 2025

The Potential Impact of Increased Recombinant Zoster Vaccine Uptake in Older Adults Worldwide.

The Potential Impact of Increased Recombinant Zoster Vaccine Uptake in Older Adults Worldwide.

Journal: Infectious diseases and therapy
Published: January 13, 2025

Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme.

Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme.

Journal: Infectious diseases and therapy
Published: September 02, 2024

Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older.

Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older.

Journal: PharmacoEconomics - open
Published: July 17, 2024

Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.

Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.

Journal: Human vaccines & immunotherapeutics
Published: May 28, 2024

The Incidence of Herpes Zoster Complications: A Systematic Literature Review.

The Incidence of Herpes Zoster Complications: A Systematic Literature Review.

Journal: Infectious diseases and therapy
Published: April 05, 2024

Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older.

Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older.

Journal: PharmacoEconomics - open
Published: March 04, 2024

Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials.

Differential Utility Losses in Herpes Zoster Cases Between Vaccinated and Unvaccinated Subjects: A Meta-analysis of Three Clinical Trials.

Journal: Clinical drug investigation
Published: March 03, 2024

Herpes Zoster Recurrence: A Narrative Review of the Literature.

Herpes Zoster Recurrence: A Narrative Review of the Literature.

Journal: Dermatology and therapy
Published: November 17, 2023

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.

Journal: Human vaccines & immunotherapeutics
Published: March 14, 2023

Public health impact of herpes zoster vaccination on older adults in Hong Kong.

Public health impact of herpes zoster vaccination on older adults in Hong Kong.

Journal: Human vaccines & immunotherapeutics
Published: February 28, 2023

Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine".

Comment on "Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine".

Journal: PharmacoEconomics
Published: August 28, 2022
Showing 1-12 of 15

Last Updated: 09/26/2026